As treatments for CLL evolve, new challenges have arisen to address the disease’s resistance to targeted therapies. The European Commission has granted Marketing Authorization for the expanded use of ibrutinib. Ibrutinib combined with standard chemoimmunotherapy significantly prolonged progression-free survival in older patients. Three-year follow-up data from the CAPTIVATE trial were presented at the 2022 ASCO Annual Meeting. The study included adults with treatment-naïve and relapsed/refractory CLL or small lymphocytic leukemia.